Zentalis completes 40% workforce cut, narrows focus to azenosertib; cash runway to late 2027

Filed March 26, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 26, 2025 · ~2 min read

Key Changes

• high

  Company completed 40% workforce reduction in 2025, cutting headcount from 166 to 106 employees. Restructuring incurred $7.8M in charges but reduced annual net loss from $165.9M to $137.1M, preserving cash runway to late 2027 despite cash declining from $371M to $246M.

  MD&A: Strategic Restructuring verify on EDGAR →
• high

  DENALI Part 2a enrollment completed in 2025; dose selection announcement planned for H1 2026. FDA-aligned Phase 3 ASPENOVA trial to initiate H1 2026, running concurrently with DENALI Part 2b. Topline readout from DENALI Part 2 expected by year-end 2026.

  Business: Clinical Development verify on EDGAR →
• high

  Discontinued further development of azenosertib in uterine serous carcinoma (USC) despite Fast Track Designation. Also terminated BRAF colorectal cancer trial. Strategic pivot narrows pipeline to platinum-resistant ovarian cancer (PROC) indication only.

  Business: Pipeline Narrowing verify on EDGAR →